Daytrana Has Same Active Ingredient Found in Ritalin and Concerta
By Todd Zwillich WebMD Medical News
Reviewed By Brunilda Nazario, MD on Thursday, April 06, 2006
April 6, 2006 – The FDA has approved the first skin patch for treating attention deficit hyperactivity disorder, despite ongoing debate about whether similar drugs should require stricter safety warnings.
The agency announced Thursday that it had approved Daytrana for use by children aged 6 to 12. The patch is manufactured by Noven Pharmaceuticals and Shire Pharmaceuticals.
Daytrana contains the active ingredient methylphenidate, the same stimulant drug used in popular oral medications such as Ritalin and Concerta.
Those drugs have recently been under scrutiny at the FDA. Two separate advisory committees have recommended stronger warnings for ADHD drugs because of reports suggesting that they may contribute to increased heart attack and stroke risk in adults and a danger of psychiatric side effects, including suicidal behaviors, in children.